Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Rovina, Nikoletta; Akinosoglou, Karolina; Eugen‐Olsen, Jesper; Hayek, Salim S.; Reiser, Jochen; Giamarellos‐Bourboulis, Evangelos J.

doi:10.1186/s13054-020-02897-4

Cited by 167 publications

(190 citation statements)

References 6 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…HIF1α participates in the regulation of a plethora of cellular events such as metabolism of ROS trough the regulation of SOD2 39 , the regulation of cytoskeleton trough VIM type III lament, which also participates in in ammation 40 , and PLAUR which activates plasminogen and activates a cascade of extracellular proteases 41 . Interestingly, the expression of this gene could be used as a predictor of severe respiratory failure 42 which is consistent with our results.…”

Section: Discussionsupporting

confidence: 91%

Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Taniguchi‐Ponciano

Vadillo

Mayani

et al. 2020

Preprint

View full text Add to dashboard Cite

Since its emergence, in December 2019, COVID-19 has resulted in more than 12 million people infected and has killed more than 570000. Hypoxemia has been identified as one of the main clinical manifestations of this disease, especially in severe cases. We have previously reported that in critically ill COVID-19 patients there is a shift towards an immature myeloid profile in peripheral blood cells, including band neutrophils, immature monocytes, metamyelocytes, monocyte-macrophages, monocytoid precursors, and promyelocytes-myelocytes, which, together with mature monocytes and segmented neutrophils, comprise the vast majority of blood cells in these patients. Such an immature myeloid profile may be the result of a physiological response known as emergency myelopoiesis. In the present study, we performed scRNAseq from leukocytes from five critically ill COVID-19 patients and characterized the expression of hypoxia-inducible factor1α (HIF1α) mRNA and its transcriptionally regulated genes. HIF1α is a master transcription factor involved in the cellular response to hypoxia. We herein report that these cellular subsets express high levels of HIF1α mRNA and several of their transcriptional targets, including those related to inflammation, such as CXCL8, CXCR1, CXCR2, and CXCR4; those potentially involved in virus sensing, such as TLR2 and TLR4; and those related to metabolism, such as SLC2A3, PFKFB3, PGK1, GAPDH and SOD2. The up-regulation and participation of HIF1α in relevant events such as inflammation, immunometabolism, and TLR make it a potential molecular marker for COVID-19 severity and, interestingly, could represent a potential target for molecular therapy.

show abstract

Section: Discussionsupporting

confidence: 91%

Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Taniguchi‐Ponciano

Vadillo

Mayani

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A relative ADAMTS13 deficiency [ 31 ], increased circulating endothelial cell (CEC) counts and serum levels of IL-6 and IL-8 [ 32 ] are observed in COVID-19, reminiscent the findings in TMA. Urokinase plasminogen activator receptor (uPAR) is bound on the endothelium and released into the blood stream as a soluble counterpart, named suPAR, in the setting of inflammation and endothelial damage [ 33 ]. Elevated suPAR level has been associated with severe COVID-19 and may serve as a prognostic factor for ARDS-associated with COVID-19 [ 33 ], which further supports the presence of endothelial injury and microangiopathy in COVID-19.…”

Section: Coagulation and Covid-19mentioning

confidence: 99%

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Wang

Sahu

Černý

2020

J Thromb Thrombolysis

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. While there are still missing links in our understanding, the interplay of endothelium, complement system activation, and immune response to the SARS-CoV-2 virus is a surprisingly major factor in COVID-19 pathogenesis. One could envision COVID-19 becoming a novel hematological syndrome. This review is to discuss the available literature with regards to the involvement of the complement system, and coagulation cascade and their interaction with endothelium.

show abstract

“…The available test allows a fast prognosis for patients, as the results can quickly be obtained on-site in the emergency room or other in-hospital settings, avoiding the need for samples to be passed through the clinical laboratory, or can even be obtained prior to hospitalization (time to result 20 min). Based on the aforementioned evidence, the suPAR could serve as a quick triage test and independent marker of clinical severity, 30-day readmission, complications, and mortality in this pandemic [10,19,35,36]. We believe that the results of ongoing trials in Germany, the UK, Denmark, Greece, and the USA will be important for clinicians worldwide.…”

Section: Soluble Urokinase Plasminogen Activator Receptormentioning

confidence: 97%

Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients

et al. 2020

View full text Add to dashboard Cite

The novel coronavirus infection has spread worldwide, causing a wide spectrum of clinical manifestations. Most patients develop moderate clinical illness, but a substantial number will experience severe pneumonia, which may rapidly progress to acute respiratory distress syndrome and multiple organ failure. In this population, soluble urokinase plasminogen activator receptor (suPAR) could serve as a quick triage test and independent marker of clinical severity, hospital and intensive care unit admission, complications, and mortality.

show abstract

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Cited by 167 publications

References 6 publications

Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients

Contact Info

Product

Resources

About